0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV371.70%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MediciNova Stock Discussion
Major Breakthrough: NIH Funds New ALS Treatment Trial for 200 Advanced-Stage Patients
13 mins ago
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
No comment yet